Lenvima
Payments companies reported to CMS as associated with Lenvima. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lenvima, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lenvima
These are the largest totals companies reported as associated with Lenvima. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Amina Ahmed | Chicago, IL | Gynecologic Oncology | $334,686.55 |
| Arnab Basu | Jacksonville, FL | Hematology & Oncology | $263,870.52 |
| Mahdi Taha | Boca Raton, FL | Medical Oncology | $252,234.40 |
| Heidi Godoy | Albany, NY | Gynecologic Oncology | $241,892.23 |
| Michael Morse | Durham, NC | Hematology & Oncology | $183,365.92 |
| John Chan | San Francisco, CA | Gynecologic Oncology | $175,378.67 |
| Justin Chura | Swedesboro, NJ | Obstetrics & Gynecology | $127,155.79 |
| Girish Kunapareddy | Terre Haute, IN | Internal Medicine | $115,966.14 |
| Chandler Park | Corydon, IN | Hematology & Oncology | $115,906.44 |
| Pierre Gholam | Cleveland, OH | Gastroenterology (Internal Medicine) | $115,415.57 |
Prescribed Lenvima?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.